Click Here: To read our COVID-19 Patient Guidelines before your visit.

  • In response to the Covid-19 pandemic, our office is following guidelines from New Jersey Department of Health.
  • For everyone's well-being, all patients and visitor must wear a face covering at all times in our office. We ask that no visitors accompany patients unless special assistance is required and then please limit to one visitor. Also please practice social distancing.
  • When arriving at our office, patients (and if necessary, visitor) will have to answer health screening questions and have their temperature checked. Anyone who is sick or had exposure to Covid will be asked to reschedule their appointment.
  • Please be assured that we are taking all precautions possible to protect our patients and staff. This includes frequent disinfection of the waiting room, patient exam rooms between patients and installing partitions between patient and staff during check-in and check-out.

Princeton Hypertension-Nephrology Associates

Nationally Designated Hypertension Practice Centers in the US by the American Society of Hypertension

Clinical Research Studies

  • ALTITUDE Study: Aliskiren Trial in Type 2 diabetes Using cardio-renal Disease Endpoints. A multicenter randomized clinical trial examining the effects of the oral direct renin inhibitor aliskiren in cardiovascular and renal outcomes among patients with type 2 diabetes mellitus. Funded by Novartis.
  • Hyponatremia Registry. An Observational Prospective Registry to Identify Demographic and Clinical Characteristics of Patients with Euvolemic and Hypervolemic Hyponatremia and Assess the Comparative Effectiveness of Available Treatments and the Impact on Resource Utilization. Funded by Otsuka America Pharmaceuticals Inc.
  • A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 2b Study to Evaluate the Safety and Efficacy of Pyridorin (pyridoxamine dihydrochloride) in Patients With Nephropathy Due to Type 2 Diabetes. Pyridoxamine, an investigational drug, is a vitamin B6 (peridoxine) derivative that has been shown to inhibit the production of advanced Gycation End products that contribute to the renal and other target organ injury of type 2 diabetes. Funded by NephroGenix, Inc.
  • The Collaborative Study Group Trial: The Effect of Sulodexide in Patients With Type 2 Diabetes and Microalbuminuria. Sulodexide is an investigational agent, has been shown experimentally to restore the glomerular protein filtration barrier and reduce proteinuria in patients with diabetic proteinuria. Funded by Keryx Biopharmaceuticals, Inc.